Biomarkers of Glucose-Insulin Homeostasis and Their Impact on Type 2 Diabetes and Cardiovascular Disease
Study Overview
This study investigates how certain biomarkers related to glucose and insulin levels can predict the risk of developing type 2 diabetes (T2D) and cardiovascular disease (CVD). It also explores whether vitamin D and omega-3 fatty acids can influence these risks.
Key Findings
- Study Design: The VITamin D and OmegA-3 TriaL (NCT01169259) was a randomized clinical trial lasting about 5.3 years.
- Participants: The study included 218 pairs of individuals with T2D and 715 pairs with CVD.
- Biomarkers Assessed: Insulin, C-peptide, HbA1c, and a new insulin resistance score (IRS) were evaluated.
- Significant Associations:
- HbA1c showed the strongest link to T2D risk.
- HbA1c was also significantly associated with CVD risk.
- IRS was linked to coronary heart disease (CHD) risk.
- No Modification: Vitamin D and omega-3 fatty acids did not change the relationship between these biomarkers and disease outcomes.
Practical Solutions and Value
Understanding these biomarkers can help in early identification and prevention of T2D and CVD. This knowledge can guide healthcare providers in:
- Implementing regular monitoring of insulin and HbA1c levels in at-risk patients.
- Utilizing AI-driven platforms like DocSym to streamline clinical practices and enhance patient care.
- Adopting mobile apps for better scheduling, treatment monitoring, and telemedicine services.
By leveraging these tools, clinics can improve workflows, reduce paperwork, and ultimately enhance patient outcomes. Learn more about our solutions at aidevmd.com.
